Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma
The effectiveness and safety profiles of first-line ICI combination therapy did not deteriorate, even in older patients. These findings suggest that ICI combination therapy for RCC should not be avoided because of chronological age alone. Geriatr Gerontol Int 2025; 25: 1082-1088.
Authors
- Toshio Takagi (ORCID: https://orcid.org/0000-0003-1775-0943)
- Koichi Nishimura (ORCID: https://orcid.org/0000-0003-0651-7484)
- Kazuhiko Yoshida (ORCID: https://orcid.org/0000-0002-3834-0153)
- Hironori Fukuda (ORCID: https://orcid.org/0009-0008-3009-0146)
- Hiroki Ishihara (ORCID: https://orcid.org/0000-0002-5146-656X)
- Yasunobu Hashimoto
- Yuki Nemoto (ORCID: https://orcid.org/0000-0003-4290-0595)
- Tsunenori Kondo (ORCID: https://orcid.org/0000-0002-9130-0855)
- Hiroaki Shimmura
- Junpei Iizuka
- Shinsuke Mizoguchi
- Takayuki Nakayama
Institutions
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
Publication Details
- Journal
- Geriatrics and gerontology international/Geriatrics & gerontology international
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1111/ggi.70105
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00